Kjellin M., Wesslén T., Löfblad E., Lennerstrand J., & Lannergård A. (2018). The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort. Upsala Journal of Medical Sciences, 123(1), 50–56. https://doi.org/10.1080/03009734.2018.1441928